Favourable response to infliximab in a case of bilateral refractory Mooren's ulcer.
A woman with progressive bilateral Mooren's ulcer developed recurrent corneal perforations and melting requiring tectonic grafts, despite conventional immunosuppressant therapy. Following treatment with infliximab, an anti-tumour necrosis factor agent, the patient showed marked reduction in conjunctival inflammation and no further recurrence of corneal thinning and perforation during 2-year follow up on maintaining treatment.
Fontana
Luigi
L
Parente
Gabriella
G
Neri
Piergiorgio
P
Reta
Massimo
M
Tassinari
Giorgio
G
D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D002908:Chronic Disease; D003320:Corneal Ulcer / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006801:Humans; D000069285:Infliximab; D008875:Middle Aged; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors
D000911:Antibodies, Monoclonal; D014409:Tumor Necrosis Factor-alpha; D000069285:Infliximab